Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Glenmark Specialty S A holds a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action for this company. This indicates a singular active matter in the current prosecution cycle, reflecting a targeted approach to their pharmaceutical intellectual property.
The portfolio's activity is limited to 1 distinct examiner and 1 distinct art unit. This concentration suggests that the company's current patenting efforts are focused on a specific area of technology. Working within 1 distinct art unit provides a consistent environment for the prosecution of these assets, as the company only needs to navigate the standards of a single administrative group.
RAMACHANDRAN, UMAMAHESWARI is the busiest examiner for Glenmark Specialty S A. This examiner is handling the 1 pending office action currently active. The progress of the company's patent applications is currently tied to the specific examination process and technical feedback provided by this individual examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAMACHANDRAN, UMAMAHESWARI | 1 | 54.9% | +53.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18392033 | TREATMENT OF ALLERGIC RHINITIS USING A COMBINATION OF MOMETASONE AND OLOPATADINE | RAMACHANDRAN, UMAMAHESWARI | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18392033 | TREATMENT OF ALLERGIC RHINITIS USING A COMBINATION OF MOMETASONE AND OLOPATADINE | RAMACHANDRAN, UMAMAHESWARI | 1627 | §103§112DP | Final Rejection | — | Pending | Dec 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGlenmark Specialty S A has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Umamaheswari Ramachandran has the most, with 1 of Glenmark Specialty S A's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.